エピソード
-
エピソードを見逃しましたか？
-
The objective of this podcast presented by Kim Linton and Renata Walewska is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with marginal zone lymphoma (MZL).
-
Antenatal screening/testing of pregnant women should be carried out according to the guidelines of the National Health Service (NHS) Sickle Cell and Thalassaemia Screening Programme. Newborn screening and, when necessary, follow-up testing and referral, should be carried out according to the guidelines of the NHS Sickle Cell and Thalassaemia Screening Programme. All babies under 1 year of age arriving in the United Kingdom should be offered screening for sickle cell disease (SCD). Preoperative screening for SCD should be carried out in patients from ethnic groups in which there is a significant prevalence of the condition. Emergency screening with a sickle solubility test must always be followed by definitive analysis. Laboratories performing antenatal screening should utilise methods that are capable of detecting significant variants and are capable of quantitating haemoglobins A2 and F at the cut-off points required by the national antenatal screening programme. The laboratory must ensure a provisional report is available for antenatal patients within three working days from sample receipt.
-
The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with mantle cell lymphoma.
-
This Good Practice Paper podcast provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.
-
Haematological management of major haemorrhage: A podcast recording of a conversation between Prof Simon Stanworth and Dr Heidi Doughty.
-
Secondary central nervous system (CNS) lymphoma (SCNSL) refers to lymphoma that has spread to the CNS concurrently with, or following treatment for, systemic lymphoma. There are three clinically distinct scenarios:Synchronous CNS and systemic lymphoma at initial presentation (treatment-naïve; TN-SCNSL),CNS relapse without recurrent systemic lymphoma (relapsed isolated CNS lymphoma; RI-SCNSL).Relapsed concomitant systemic and CNS disease following treatment for systemic lymphoma (RC-SCNSL).
CNS lymphoma (CNSL) is associated with inferior outcomes, which may be attributed to several factors: poor CNS penetrance of chemotherapeutics, including RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone),1 impaired neurocognitive function and patient performance status (PS) contributing to increased treatment toxicity,2, 3 and recurrent genetic aberrations conferring treatment resistance.4-6 The rarity and heterogeneity of SCNSL also limits the evidence base for treatment recommendations, with poor outcomes potentially attributable at least in part to lack of optimised treatment protocols.
This good practice paper focuses on diffuse large B-cell lymphoma (DLBCL), the most common SCNSL subtype. It covers diagnostic and therapeutic aspects of care for the three SCNSL scenarios and multiply relapsed SCNSL. Treatment recommendations are framed by patient fitness and treatment intent.
-
This guideline updates and widens the scope of the previous British Society for Haematology (BSH) Clinical guidelines for testing for heritable thrombophilia1 to include both heritable and acquired thrombophilia.
The term thrombophilia is generally used to describe hereditary and/or acquired conditions associated with an increased predisposition to thrombosis. Heritable thrombophilia refers to genetic disorders of specific haemostatic proteins. These guidelines focus only on the factors that are identified from laboratory testing and therefore exclude disorders such as cancer, inflammatory conditions and obesity that are associated with thrombosis through multiple mechanisms.
-
British Society for Haematology Annual Scientific Meeting Guidelines Session 2022
Dr Suzy Morton on the Good Practice Paper Cytomegalovirus serological testing in potential allogeneic haematopoietic stem cell transplant recipients.
Dr Suzy Morton is a Consultant in clinical haematology and blood transfusion at the Queen Elizabeth Hospital, University Hospitals Birmingham and NHS Blood and Transplant. She is the transfusion representative on the West Midlands Haematology Specialty Training Committee and the educational lead for haematology SpRs at QEHB. Suzy is a transfusion representative on the BSH Education committee.
-
British Society for Haematology Annual Scientific Meeting Guidelines Session 2022
Dr Katie Hands presents on the Good Practice Paper Preoperative patient blood management during the SARS-CoV-2 pandemic.
Katie Hands is a Consultant Haematologist with the Scottish National Blood Transfusion Service (SNBTS) based at Ninewells Hospital, Dundee. She is a member of the British Society for Haematology Transfusion Task Force and is involved in the preparation of evidence-based guidelines relating to all aspects of blood transfusion in the United Kingdom.
-
British Society for Haematology Annual Scientific Meeting Guidelines Session 2022
Dr Austin Kulasekararaj presents on the Myelodysplastic syndromes covering the BSH Guidelines on the diagnosis and prognosis of adult myelodysplastic syndromes and Guidelines on the management of adult myelodysplastic syndromes.
Dr Austin Kulasekararaj is a Consultant Haematologist at the King's College Hospital London. His special interests are adult myelodysplastic syndromes, acute leukaemia and aplastic anaemia.
-
British Society for Haematology Annual Scientific Meeting Guidelines Session 2022
Dr Dima ElSharkawi presents the Guideline on the Diagnosis and Management of Waldenstrom Macroglobulinaemia.
Dr Dima El-Sharkawi is a Consultant Haematologist and part of the haematological malignancy diagnostic services at the Royal Marsden NHS Foundation Trust. She is also a Trustee for the UK Charity for Waldenström macroglobulinaemia (WMUK). Dr El-Sharkawi's special interests are in CLL, rare leukaemias and lymphomas including Waldenström macroglobulinaemia.
-
Dr Nilima Parry Jones and Dr Renata Walewska present a podcast on the Guideline for the treatment of chronic lymphocytic leukaemia
Both Dr Parry Jones and Dr Walewska discuss the guideline in three main parts:
1) Choice of treatment for CLL in front line and relapsed settings
2) Impact to immune dysregulation in respect of anti-microbial prophylaxis and vaccination
3) Challenges of the Covid pandemic, the evolving evidence on vaccine response, treatment of patients with Covid and antiviral and monoclonal antibodies
Dr Nilima Parry-Jones is a Consultant Haematologist at the Aneurin Bevan Local Health, Wales and an executive member of the UK CLL Forum. She is the Chair of the BSH Haematology Oncology Task Force.
Dr Renata Walewska is a Consultant Haematologist at the Royal Bournemouth Hospital and Chair of the UK CLL Forum.
- もっと表示する
